Sarepta Therapeutics stock (US8036071004): Q1 earnings beat estimates amid share price decline

Sarepta Therapeutics reported Q1 EPS of $3.16, topping consensus by $2.18, yet shares fell 12.5% YTD to $18.84 as of May 2026.

Sarepta Therapeutics released its first-quarter 2026 earnings on May 6, reporting earnings per share of $3.16, which exceeded analyst expectations of $0.98 according to MarketBeat as of May 2026. Despite the earnings beat, the stock has declined 12.5% year-to-date from $21.52 on January 1, 2026, trading at $18.84 on Nasdaq as of recent data. Investors appeared disappointed, possibly due to one-time items boosting profits, per analysis from Simply Wall St as of May 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Sarepta Therapeutics, Inc.
• Sector/industry: Pharmaceuticals & Biotech
• Headquarters/country: United States
• Core markets: Rare neuromuscular diseases
• Key revenue drivers: Precision genetic medicines
• Home exchange/listing venue: Nasdaq (SRPT)
• Trading currency: USD

Sarepta Therapeutics: core business model

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare diseases, particularly neuromuscular disorders. It develops RNA-targeted therapeutics, siRNA platforms, gene therapies, and other genetic modalities, as described in its corporate overview on Simply Wall St as of May 2026. The company positions itself as a leader in this niche, targeting conditions with high unmet needs.

Main revenue and product drivers for Sarepta Therapeutics

Revenue primarily stems from approved genetic therapies for rare neuromuscular diseases. Key products drive sales in the US market, where Sarepta holds significant exposure for American investors tracking biotech innovation. Recent Q1 2026 results highlighted profitability, though sustainability concerns linger due to unusual items.

Industry trends and competitive position

The biotech sector for rare diseases sees growing demand for gene therapies amid advances in precision medicine. Sarepta competes in a specialized field, benefiting from regulatory approvals that enhance its pipeline value for US-listed biotechs.

Why Sarepta Therapeutics matters for US investors

Listed on Nasdaq, Sarepta offers US investors direct access to cutting-edge genetic medicine developments. Its focus on rare diseases aligns with sector growth, providing exposure to high-potential therapies amid a $1.99 billion market cap as of May 2026 data from MarketBeat.

Conclusion

Sarepta Therapeutics delivered a strong Q1 earnings beat, yet shares remain down YTD amid profit quality questions. The company's leadership in genetic medicines for rare diseases continues to drive interest. Ongoing conferences like the RBC Capital Markets event signal active engagement with investors.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.